S&P 500   3,112.11 (-0.02%)
DOW   27,627.17 (-0.08%)
QQQ   202.40 (-0.01%)
AAPL   264.35 (+1.00%)
FB   198.69 (-0.01%)
MSFT   149.84 (+-0.01%)
GOOGL   1,318.89 (+0.00%)
AMZN   1,747.61 (-0.74%)
CGC   18.79 (+2.23%)
NVDA   208.81 (-0.29%)
MU   46.48 (+0.39%)
BABA   199.58 (+3.01%)
GE   10.84 (-0.55%)
TSLA   330.46 (-0.77%)
T   38.29 (+0.50%)
AMD   40.00 (+0.76%)
NFLX   300.45 (-1.27%)
BAC   33.08 (-0.21%)
GILD   65.71 (-1.56%)
DIS   147.93 (-0.24%)
S&P 500   3,112.11 (-0.02%)
DOW   27,627.17 (-0.08%)
QQQ   202.40 (-0.01%)
AAPL   264.35 (+1.00%)
FB   198.69 (-0.01%)
MSFT   149.84 (+-0.01%)
GOOGL   1,318.89 (+0.00%)
AMZN   1,747.61 (-0.74%)
CGC   18.79 (+2.23%)
NVDA   208.81 (-0.29%)
MU   46.48 (+0.39%)
BABA   199.58 (+3.01%)
GE   10.84 (-0.55%)
TSLA   330.46 (-0.77%)
T   38.29 (+0.50%)
AMD   40.00 (+0.76%)
NFLX   300.45 (-1.27%)
BAC   33.08 (-0.21%)
GILD   65.71 (-1.56%)
DIS   147.93 (-0.24%)
S&P 500   3,112.11 (-0.02%)
DOW   27,627.17 (-0.08%)
QQQ   202.40 (-0.01%)
AAPL   264.35 (+1.00%)
FB   198.69 (-0.01%)
MSFT   149.84 (+-0.01%)
GOOGL   1,318.89 (+0.00%)
AMZN   1,747.61 (-0.74%)
CGC   18.79 (+2.23%)
NVDA   208.81 (-0.29%)
MU   46.48 (+0.39%)
BABA   199.58 (+3.01%)
GE   10.84 (-0.55%)
TSLA   330.46 (-0.77%)
T   38.29 (+0.50%)
AMD   40.00 (+0.76%)
NFLX   300.45 (-1.27%)
BAC   33.08 (-0.21%)
GILD   65.71 (-1.56%)
DIS   147.93 (-0.24%)
S&P 500   3,112.11 (-0.02%)
DOW   27,627.17 (-0.08%)
QQQ   202.40 (-0.01%)
AAPL   264.35 (+1.00%)
FB   198.69 (-0.01%)
MSFT   149.84 (+-0.01%)
GOOGL   1,318.89 (+0.00%)
AMZN   1,747.61 (-0.74%)
CGC   18.79 (+2.23%)
NVDA   208.81 (-0.29%)
MU   46.48 (+0.39%)
BABA   199.58 (+3.01%)
GE   10.84 (-0.55%)
TSLA   330.46 (-0.77%)
T   38.29 (+0.50%)
AMD   40.00 (+0.76%)
NFLX   300.45 (-1.27%)
BAC   33.08 (-0.21%)
GILD   65.71 (-1.56%)
DIS   147.93 (-0.24%)
Log in

OTCMKTS:ENDV - Endonovo Therapeutics Stock Price, Forecast & News

$0.0029
0.00 (0.00 %)
(As of 12/5/2019 12:08 PM ET)
Today's Range
$0.00
Now: $0.00
$0.00
50-Day Range
$0.00
MA: $0.01
$0.01
52-Week Range
$0.00
Now: $0.00
$0.04
Volume4.41 million shs
Average Volume4.53 million shs
Market Capitalization$2.63 million
P/E RatioN/A
Dividend YieldN/A
Beta2.14
Endonovo Therapeutics, Inc. develops non-invasive electrocuetical devices for regenerative medicine. It is developing Electroceutical Therapy for the treatment of pain and post-surgical edema with a concentration on cosmetic surgeries, including breast augmentation, reduction and reconstruction surgery, rhinoplasty, and liposuction procedures. The company was incorporated in 2008 and is headquartered in Woodland Hills, California.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ENDV
CUSIPN/A
Phone800-489-4774

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$80,000.00
Book Value($0.03) per share

Profitability

Net Income$-6,440,000.00
Net Margins-5,033.33%

Miscellaneous

EmployeesN/A
Market Cap$2.63 million
Next Earnings Date4/20/2020 (Estimated)
OptionableNot Optionable

Receive ENDV News and Ratings via Email

Sign-up to receive the latest news and ratings for ENDV and its competitors with MarketBeat's FREE daily newsletter.


Endonovo Therapeutics (OTCMKTS:ENDV) Frequently Asked Questions

What is Endonovo Therapeutics' stock symbol?

Endonovo Therapeutics trades on the OTCMKTS under the ticker symbol "ENDV."

When is Endonovo Therapeutics' next earnings date?

Endonovo Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, April 20th 2020. View Earnings Estimates for Endonovo Therapeutics.

Has Endonovo Therapeutics been receiving favorable news coverage?

News stories about ENDV stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Endonovo Therapeutics earned a daily sentiment score of 0.9 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Endonovo Therapeutics.

Who are some of Endonovo Therapeutics' key competitors?

What other stocks do shareholders of Endonovo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Endonovo Therapeutics investors own include Energous (WATT), Eyegate Pharmaceuticals (EYEG), PotNetwork (POTN), BIOLINERX LTD/S (BLRX), Cara Therapeutics (CARA), Marinus Pharmaceuticals (MRNS), SCYNEXIS (SCYX), Chesapeake Energy (CHK), Terra Tech (TRTC) and Adamis Pharmaceuticals (ADMP).

Who are Endonovo Therapeutics' key executives?

Endonovo Therapeutics' management team includes the folowing people:
  • Mr. Alan Brian Collier, Chairman, CEO, Interim CFO & Sec. (Age 53)
  • Mr. Michael Scott Mann, Pres (Age 62)
  • Mr. Donald Calabria, Chief Operating Officer
  • Mr. Steven Barnes, Sr. VP of Investor Relations
  • Bruce Garfield, Vice-Pres of Sales & Marketing

How do I buy shares of Endonovo Therapeutics?

Shares of ENDV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Endonovo Therapeutics' stock price today?

One share of ENDV stock can currently be purchased for approximately $0.00.

How big of a company is Endonovo Therapeutics?

Endonovo Therapeutics has a market capitalization of $2.63 million and generates $80,000.00 in revenue each year. View Additional Information About Endonovo Therapeutics.

What is Endonovo Therapeutics' official website?

The official website for Endonovo Therapeutics is http://www.endonovo.com/.

How can I contact Endonovo Therapeutics?

Endonovo Therapeutics' mailing address is 6320 CANOGA AVENUE 15TH FLOOR, WOODLAND HILLS CA, 91367. The biotechnology company can be reached via phone at 800-489-4774 or via email at [email protected]


MarketBeat Community Rating for Endonovo Therapeutics (OTCMKTS ENDV)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  70 (Vote Outperform)
Underperform Votes:  101 (Vote Underperform)
Total Votes:  171
MarketBeat's community ratings are surveys of what our community members think about Endonovo Therapeutics and other stocks. Vote "Outperform" if you believe ENDV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENDV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/5/2019 by MarketBeat.com Staff

Featured Article: What is the S&P/TSX Index?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel